Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Net Cash Flow: 2019-2024

Historic Net Cash Flow for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to -$99.8 million.

  • 4D Molecular Therapeutics' Net Cash Flow fell 1779.37% to -$28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$139.8 million, marking a year-over-year decrease of 58.67%. This contributed to the annual value of -$99.8 million for FY2024, which is 150.71% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Net Cash Flow of -$99.8 million as of FY2024, which was down 150.71% from $196.8 million recorded in FY2023.
  • 4D Molecular Therapeutics' 5-year Net Cash Flow high stood at $227.1 million for FY2020, and its period low was -$123.7 million during FY2021.
  • In the last 3 years, 4D Molecular Therapeutics' Net Cash Flow had a median value of -$99.8 million in 2024 and averaged -$1.2 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first spiked by 639.25% in 2020, then tumbled by 154.49% in 2021.
  • Over the past 5 years, 4D Molecular Therapeutics' Net Cash Flow (Yearly) stood at $227.1 million in 2020, then slumped by 154.49% to -$123.7 million in 2021, then grew by 18.65% to -$100.7 million in 2022, then surged by 295.49% to $196.8 million in 2023, then plummeted by 150.71% to -$99.8 million in 2024.